ExoProTher milestone achieved

Nov 11, 2020

I am pleased to share with our followers and investors the latest in vivo results.



Two weeks ago, a successful in vivo experiment on mouse model of colon cancer ended with impressive results. Life span of treated mice was significantly prolonged after single dose of Exo, while 25% of them remained tumor-free after the experiment completion. Additional in vivo studies using other cancer models are in progress.



Best regards,

Lana Volokh - CEO